ArticleScientific reports2025
Conditional immortalization of olfactory ensheathing cells for intelligently regulating their proliferation state.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Olfactory ensheathing cells (OECs) are among the most promising cell types for the treatment of spinal cord injury (SCI) and other neural traumas. However, primary OECs cultured in vitro are constrained by their inherent "Hayflick limit," resulting in poor proliferative and passaging capacities, which restricts their large-scale application in both basic and clinical research. Conditional immortalization technology provides an excellent solution for rapid, large-scale, and controllable proliferation of primary OECs. However, few studies have applied this approach to the controlled passaging of OECs. Here, we used the tetracycline-controlled system (Tet-On system) to introduce the HBLV-TetOn-SV40Tag-PURO constructed into the primary OECs via lentiviral transfection, establishing a conditionally immortalized OEC line. We comprehensively investigated its functional characteristics with or without tetracycline conditions by using immunofluorescence, qPCR, CCK-8, Scratch assay, and Transwell migration experiment. Our results demonstrated that this cell line could rapidly proliferate under tetracycline and quickly recover to proliferation and migration levels similar to primary OECs after tetracycline removal following multiple passages. This approach ensures obtaining a suitable quantity of OECs with specific functional characteristics while avoiding the malignant proliferation risks associated with traditional cell line establishment, thus offering higher safety. Moreover, the method is simple to operate, cost-effective, possessing excellent potential for basic and clinical translational applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.